International Clinical Trials in Endocrinology

Argentina

• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Buenos Aires ; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Buenos Aires ; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Rosario; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  San Martín; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Santa Fe; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Villa Domínico; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Buenos Aires ; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Rosario; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Santa Fe; Research Site:
  
  

Australia

• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Adelaide; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Sydney; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  Adelaide; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  Canberra; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  St. Leonards; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Adelaide; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Sydney; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Adelaide; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Heidelberg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Sydney; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Freemantle; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Sydney; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Adelaide; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  St. Leonards; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
  Heidelberg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Adelaide; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Sydney; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Melbourne; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  St. Leonards; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Sydney; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Adelaide; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Ballarat; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Brisbane; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Canberra; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Frankston; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Liverpool; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  St. Leonards; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Sydney; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Adelaide; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Heidelberg; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Melbourne; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  St. Leonards; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Sydney; Research Site:
  
  

Austria

• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Salzburg; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Wien; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Graz; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Salzburg; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Wien; Research Site:
  
  

Belgium

• Diabetes Mellitus, Type 2: A Study to Evaluate the Effect of GK Activator (2) on QT Interval in Patients With Type 2 Diabetes Mellitus.
  Antwerpen; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Bruxelles; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Leuven; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Wilrijk; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Antwerpen; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Bruxelles; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Gent; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Leuven; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Liege; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Antwerpen; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Bruxelles; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Leuven; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Wilrijk; Research Site:
  
  

Brazil

• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  Sao Paulo; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Belem - Pa; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Brasilia; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Campinas - Sp; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Curitiba; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Fortaleza; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Fortaleza - Ce; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Goiania - Go; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Maringa - Pr; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Mogi Das Cruzes - Sp; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Porto Alegre; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Santos; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Sao Paulo; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Sao Paulo - Sp; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Belem - Pa; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Brasilia; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Campina Grande Do Sul; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Campinas; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Campinas - Sp; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Fortaleza; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Fortaleza - Ce; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Goiania - Go; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Maringa - Pr; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Mogi Das Cruzes - Sp; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Porto Alegre; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Recife; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Rio De Janeiro; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Sao Paulo; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Sao Paulo - Sp; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  São Paulo - Sp; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Brasilia; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Campinas - Sp; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Forlateza; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Fortaleza; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Fortaleza - Ce; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Goiania - Go; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Maringa - Pr; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Mogi Das Cruzes - Sp; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Passo Fundo; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Porto Alegre; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Recife; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Rio De Janeiro; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Sao Paulo; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  São Paulo; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Sao Paulo - Sp; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Belo Horizonte; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Curitiba - Pr; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Ijuí; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Jaú; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Porto Alegre; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Porto Alegre - Rs; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Porto Alegre Rs; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Salvador; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Sao Paulo; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Belo Horizonte; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Ijuí; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Salvador; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Santo Andre; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Sao Paulo; Research Site:
  
  

Bulgaria

• Diabetes Mellitus, Type 2: A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
  Stara Zagora; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Dimitrovgrad; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Pleven; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Ruse; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Sofia; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Varna; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Ruse; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Sofia; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Dimitrovgrad; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Pleven; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Ruse; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Sofia; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Dimitrovgrad; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Pleven; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Plovdiv; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Sofia; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Gabrovo; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Pleven; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Plovdiv; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Sofia; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Varna; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Vratza; Research Site:
  
  

Canada

• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Halifax, NS; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  London, ON; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Toronto, ON; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Winnipeg, MB; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  London, ON; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Montreal, QC; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Vancouver, BC; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  London, ON; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Pointe-Claire, QC; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Toronto, ON; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  London, ON; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Pointe-Claire, QC; Research Site:
  
  
• Diabetic Macular Edema: Diabetic Macular Edema
  Mississauga, Ontario; Canadian Centre for Advanced Eye Therapeutics
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Calgary, AB; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Kelowna, BC; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Vancouver, BC; Research Site:
  
  
• Ovarian Cancer: National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
  Edmonton; Cross Cancer Institute
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Edmonton, AB; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Mississauga, ON; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Toronto, ON; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Edmonton, AB; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Montreal, QC; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Ottawa, ON; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Quebec City, QC; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Toronto, ON; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Vancouver, BC; Research Site:
  
  

China

• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Hong Kong; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Hong Kong; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  Hong Kong; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Hong Kong; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Hong Kong; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Beijing; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Shanghai; Research Site:
  
  

Costa Rica

• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  San José; Research Site:
  
  

Croatia

• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Zagreb; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Zagreb; Research Site:
  
  

Czech Republic

• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Brno; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Hradec Kralove; Research Site:
  
  

Denmark

• Diabetes Mellitus, Type 2: A Drug-Drug Interaction Study of GK Activator (2) and Ethanol in Patients With Type 2 Diabetes.
  København; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Aalborg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Ballerup; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Vejle; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Copenhagen Oe (Ø); Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Herlev; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Hillerød; Research Site:
  
  

Estonia

• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Tartu; Research Site:
  
  

Finland

• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Helsinki; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Kuopio; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Oulu; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Turku; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Helsinki; Research Site:
  
  

France

• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Corbeil-Essonnes; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Montpellier; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Narbonne; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Paris; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Bondy; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Dijon; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Nantes; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Narbonne; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Besancon; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Corbeil-Essonnes; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Narbonne; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Paris; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Poitiers; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Besancon; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Villejuif; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Angers; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Besancon; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Brest; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Paris; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Saint Priest En Jarez; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Besancon; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Bordeaux; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Boulogne-Billancourt; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Clichy; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Limoges; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Marseille; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Paris; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Saint Herblain; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Strasbourg; Research Site:
  
  
• Post-Menopausal Osteopenia: A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
  Lyon; Research Site:
  
  
• Post-Menopausal Osteopenia: A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
  Paris; Research Site:
  
  
• Post-Menopausal Osteopenia: A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
  Saint-Etienne; Research Site:
  
  
• Post-Menopausal Osteopenia: A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
  Toulouse; Research Site:
  
  

Germany

• Diabetes Mellitus, Type 1: Starting Basal Rate Profiles Used in Continuous Subcutaneous Insulin Infusion.
  Ulm; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Drug-Drug Interaction Study of GK Activator (2) and Ethanol in Patients With Type 2 Diabetes.
  München; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Glimepiride.
  Berlin; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Glimepiride.
  Mainz; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
  Berlin; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
  Neuss; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.
  Neuss; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Bad Lauterberg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Berlin; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Görlitz; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Hannover; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Mainz; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Neuss; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Nürnberg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Bad Lauterberg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Berlin; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Dresden; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Görlitz; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Mainz; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Neuss; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Bammental; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Berlin; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Essen; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Giessen; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Görlitz; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Hamburg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Kuenzing; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Mannheim; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Nürnberg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
  Tann; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Aschaffenburg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Berlin; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Damme; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Dresden; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Essen; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Falkensee; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Hamburg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Ludwigshafen; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Mainz; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  München; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Münster; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Neuwied; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Nürnberg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Pirna; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Rhaunen; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Villingen-Schwenningen; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Zwenkau; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Mainz; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study to Evaluate the Effect of GK Activator (2) on QT Interval in Patients With Type 2 Diabetes Mellitus.
  Neuss; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
  Berlin; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
  Giessen; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
  Görlitz; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
  Nürnberg; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Berlin; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  München; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Neuss; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Bochum; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Dresden; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Esslingen; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Frankfurt Am Main; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Greifswald; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Hamburg; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Köln; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Magdeburg; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Saarbruecken; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Ulm; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Berlin; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Bochum; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Bonn; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Esslingen; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Frankfurt Am Main; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Halle; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Hamburg; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Hamm; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Kaiserslautern; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Leipzig; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Marburg; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Münchengladbach; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Saarbruecken; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Trier; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Ulm; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Berlin; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Bochum; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Bonn; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Hamburg; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Heidelberg; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Leipzig; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Magdeburg; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Mainz; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  München; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Münchengladbach; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Trier; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Ulm; Research Site:
  
  
• Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
  Esslingen; Research Site:
  
  
• Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
  Freiburg; Research Site:
  
  
• Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
  Heidelberg; Research Site:
  
  
• Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
  Mannheim; Research Site:
  
  
• Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
  München; Research Site:
  
  
• Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
  Regensburg; Research Site:
  
  
• Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
  Schweinfurt; Research Site:
  
  
• Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
  Tübingen; Research Site:
  
  
• Pancreatic Cancer: A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer
  Ulm; Research Site:
  
  

Greece

• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Nikea; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Thessaloniki; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Heraklion; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Thessaloniki; Research Site:
  
  

Guatemala

• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Guatemala City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  Guatemala City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Guatemala City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Guatemala; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Guatemala; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Guatemala; Research Site:
  
  

Hungary

• Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
  Balatonfuered; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
  Budapest; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Budapest; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Gyor; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Kecskemet; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Budapest; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Debrecen; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Gyor; Research Site:
  
  

India

• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Bangalore; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Chennai; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Jaipur; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Kochi; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Kolkata; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Mumbai; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  New Delhi; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Pune; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Vellore; Research Site:
  
  

Israel

• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Beer Sheva; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Haifa; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Holon; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Jerusalem; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Kfar Saba; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Petach Tikva; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Ramat Gan; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Tel Aviv; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Haifa; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Holon; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Jerusalem; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Kfar Saba; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Petach Tikva; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Tel Aviv; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Haifa; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Tel Aviv; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Zerifin; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Kfar Saba; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Petah Tikva; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Rehovot; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Tel Aviv; Research Site:
  
  

Italy

• Diabetes Mellitus, Type 1: A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine.
  Bergamo; Research Site:
  
  
• Diabetes Mellitus, Type 1: A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine.
  Brescia; Research Site:
  
  
• Diabetes Mellitus, Type 1: A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine.
  Padova; Research Site:
  
  
• Diabetes Mellitus, Type 1: A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine.
  Pisa; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Bologna; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Genova; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Perugia; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Siena; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Torino; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Ancona; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Napoli; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Udine; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Genova; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Olbia; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Pavia; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Pordenone; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Siena; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Ancona; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Asti; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Bari; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Bassano del Grappa; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Bergamo; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Catania; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Catanzaro; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Foggia; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Forli; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Genova; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Messina; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Milano; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Monfalcone; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Olbia; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Padova; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Palermo; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Perugia; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Pescara; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Prato; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Quartu S. Elena-Cagliari; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Roma; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  S.Benedetto del Tronto (AP); Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Salerno; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Siena; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Terni; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Torino; Research Site:
  
  
• Diabetes Mellitus, Type 2: Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.
  Udine; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Milano; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Parma; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Bologna; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Ferrara; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Firenze; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Udine; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Chieti; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Firenze; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Napoli; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Orbassano; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Pordenone; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  San Giovanni Rotondo; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Udine; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Bologna; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Chieti; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Genova; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Napoli; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Orbassano; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Parma; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  San Giovanni Rotondo; Research Site:
  
  
• Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
  Bari; Research Site:
  
  
• Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
  Bologna; Research Site:
  
  
• Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
  Catania; Research Site:
  
  
• Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
  Ferrara; Research Site:
  
  
• Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
  Napoli; Research Site:
  
  
• Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
  Pavia; Research Site:
  
  
• Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
  Perugia; Research Site:
  
  
• Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
  Pisa; Research Site:
  
  
• Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
  Pordenone; Research Site:
  
  
• Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
  Roma; Research Site:
  
  
• Pancreatic Cancer: A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.
  Verona; Research Site:
  
  

Latvia

• Diabetes Mellitus, Type 2: A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
  Jelgava; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
  Riga; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Riga; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Ogre; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Riga; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Riga; Research Site:
  
  

Lithuania

• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Kaunas; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Klaipeda; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Vilnius; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Klaipeda; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Vilnius; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Kaunas; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Vilnius; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Vilnius Lt; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Vilnius; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Vilnius Lt; Research Site:
  
  

Malaysia

• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Kuala Lumpur; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Penang; Research Site:
  
  

Mexico

• Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
  Chihuahua; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
  Hermosillo; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
  Metepec; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
  Mexico City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
  Monterrey; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
  Tlalpan; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
  Zapopan; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
  Chihuahua; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
  Guadalajara; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
  Pachuca; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Guadalajara; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Mexico City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Monterrey; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Pachuca; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Aguascalientes; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Chihuahua; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Cuernavaca; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Durango; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Guadalajara; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Mexico City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Monterrey; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Aleglitazar in Patients With Type 2 Diabetes
  Pachuca; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  Aguascalientes; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  Chihuahua; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  Guadalajara; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  Mexico City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  Pachuca; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV (3) in Patients With Type 2 Diabetes.
  Tampico; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Chihuahua; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Guadalajara; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Mexico City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Monterrey; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
  Pachuca; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Chihuahua; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Cuernavaca; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Durango; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
  Mexico City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Acapulco; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Aguascalientes; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Chihuahua; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Durango; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Guadalajara; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Mexico City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Monterrey; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Tampico; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Acapulco; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Aguascalientes; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Chihuahua; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Hermosillo; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Mexico City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Morelia; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Chihuahua; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Guadalajara; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Mexico City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
  Morelia; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
  Chihuahua; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
  Cuernavaca; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
  Mexico City; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Chihuahua; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Culiacan; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Monterrey; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Tampico; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Mexico City; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Mexico City; Research Site:
  
  

Netherlands

• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Amsterdam; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Amsterdam; Research Site:
  
  

New Zealand

• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Auckland; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Auckland; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Christchurch; Research Site:
  
  

Peru

• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Arequipa; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
  Lima; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
  Lima; Research Site:
  
  
• Diabetes Mellitus, Type 2: A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
  Lima; Research Sit